Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation
A. Richardson(Shell (Netherlands)), Alexandra Santana Sorensen(Evolva (Switzerland)), Pēteris Alberts(Maxygen (United States)), Jean‐Philippe Meyer(Evolva (Switzerland)), Kjell S. Sakaríassen(Ospedale degli Infermi)
Cited by 8
Related Papers
Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains
|Endocrinology|2003|263
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
|Diabetologia|2002|259
Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1
|Journal of Medicinal Chemistry|2002|211
The advent of oncolytic virotherapy in oncology: The Rigvir® story
|European Journal of Pharmacology|2018|179